CASE SETTLED
Final approval of a $98 million class settlement for direct purchasers.
Case Status
Settled
Class Certified
Settlement Value
$98 Million
Case Caption
In re: PROGRAF ANTITRUST LITIGATION
Position
Co-Lead Counsel
Attorneys
Practice Areas
Court
U.S. District Court for the District of Massachusetts
Judge Assigned
Hon. Rya Zobel
Case Number
1:11-md-02242
Defendant(S)
Astellas Pharma US LLC
File Date
In April 2015, Hagens Berman, as court-appointed co-lead class counsel, moved for final approval of a $98 million class settlement for direct purchasers in the Prograf antitrust MDL. The direct purchaser class plaintiffs allege Astellas submitted a sham petition to the U.S. Food and Drug Administration to delay approval of generic versions of the immunosuppressant Prograf.
The antitrust MDL, which was first consolidated in June 2011, alleged that Astellas violated antitrust laws by filing petition with the FDA as a means of delaying entry of a generic version of Prograf, a drug used to prevent organ rejection by kidney, liver, heart and lung transplant patients.
